Marshall Wace’s Dianthus Therapeutics DNTH Stock Holding History

Marshall Wace’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.5M	Sell	128,743 -213,186	-62%	-$18.6M	0.01%	939
2026 Q1	$28.7M	Sell	341,929 -666,604	-66%	-$38.6M	0.03%	568
2025 Q4	$41.6M	Buy	1,008,533 +435,595	+76%	+$16.9M	0.04%	392
2025 Q3	$22.5M	Buy	+572,938	New	+$14.6M	0.02%	603
2024 Q4	–	Sell	-53,848	Closed	-$1.47M	–	2670
2024 Q3	$1.47M	Sell	53,848 -54,351	-50%	-$1.51M	﹤0.01%	1491
2024 Q2	$2.8M	Sell	108,199 -4,731	-4%	-$114K	﹤0.01%	1219
2024 Q1	$3.39M	Buy	+112,930	New	+$2.45M	0.01%	1152
2023 Q2	–	Sell	-9,854	Closed	-$125K	–	2562
2023 Q1	$125K	Buy	+9,854	New	+$109K	﹤0.01%	2476
2021 Q3	–	Sell	-936	Closed	-$146K	–	3098
2021 Q2	$146K	Buy	+936	New	+$172K	﹤0.01%	2499
2021 Q1	–	Sell	-4,563	Closed	-$572K	–	2552
2020 Q4	$572K	Hold	4,563	–	–	﹤0.01%	1413
2020 Q3	$496K	Sell	4,563 -5,388	-54%	-$638K	﹤0.01%	1249
2020 Q2	$1.2M	Buy	+9,951	New	+$1.4M	0.01%	948

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Marshall Wace's DNTH Position: Q2 2026 in Review

Marshall Wace reduced its Dianthus Therapeutics (DNTH) stake by 62% in Q2 2026, selling an estimated $18.6M and leaving 128,743 shares worth $12.5M. The position accounts for 0.01% of the portfolio, ranked #939.

Marshall Wace first reported a position in DNTH in Q2 2020 and has held it in 12 quarters since. The position peaked at $41.6M in Q4 2025. 268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Marshall Wace held 128,743 shares of Dianthus Therapeutics worth $12.5M as of Q2 2026.
Marshall Wace sold 213,186 Dianthus Therapeutics shares in Q2 2026, an estimated $18.6M.
Dianthus Therapeutics made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #939 holding.
Marshall Wace first reported a position in Dianthus Therapeutics in Q2 2020 and has held it in 12 quarters since.
Marshall Wace's Dianthus Therapeutics position peaked at $41.6M in Q4 2025.
268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.